BMP7-Loaded Human Umbilical Cord Mesenchymal Stem Cell-Derived Small Extracellular Vesicles Ameliorate Liver Fibrosis by Targeting Activated Hepatic Stellate Cells
Dan Zhu,Zongbin Sun,Jiayun Wei,Yulin Zhang,Wenjing An,Yan Lin,Xun Li
DOI: https://doi.org/10.2147/ijn.s450284
IF: 7.033
2024-04-11
International Journal of Nanomedicine
Abstract:Dan Zhu, 1 Zongbin Sun, 1 Jiayun Wei, 2 Yulin Zhang, 2 Wenjing An, 2 Yan Lin, 1 Xun Li 1– 3 1 First Clinical Medical College, Lanzhou University, Lanzhou, People's Republic of China; 2 Gansu Province Key Laboratory of Biotherapy and Regenerative Medicine, First Hospital of Lanzhou University, Lanzhou University, Lanzhou, People's Republic of China; 3 General Surgery Department, First Hospital of Lanzhou University, Lanzhou University, Lanzhou, People's Republic of China Correspondence: Xun Li, First Hospital of Lanzhou University, 1st West Donggang Road, Chengguan District, Lanzhou, Gansu Province, 730000, People's Republic of China, Tel +86-931-8356056, Fax +86-931-8629797, Email Purpose: Human umbilical cord mesenchymal stem cell (hucMSC)-derived small extracellular vesicles (sEVs) are natural nanocarriers with promising potential in treating liver fibrosis and have widespread applications in the fields of nanomedicine and regenerative medicine. However, the therapeutic efficacy of natural hucMSC-sEVs is currently limited owing to their non-specific distribution in vivo and partial removal by mononuclear macrophages following systemic delivery. Thus, the therapeutic efficacy can be improved through the development of engineered hucMSC-sEVs capable to overcome these limitations. Patients and Methods: To improve the anti-liver fibrosis efficacy of hucMSC-sEVs, we genetically engineered hucMSC-sEVs to overexpress the anti-fibrotic gene bone morphogenic protein 7 ( BMP7 ) in parental cells. This was achieved using lentiviral transfection, following which BMP7-loaded hucMSC-sEVs were isolated through ultracentrifugation. First, the liver fibrosis was induced in C57BL/6J mice by intraperitoneal injection of 50% carbon tetrachloride (CCL4) twice a week for 8 weeks. These mice were subsequently treated with BMP7+sEVs via tail vein injection, and the anti-liver fibrosis effect of BMP7+sEVs was validated using small animal in vivo imaging, immunohistochemistry (IHC), tissue immunofluorescence, and enzyme-linked immunosorbent assay (ELISA). Finally, cell function studies were performed to confirm the in vivo results. Results: Liver imaging and liver histopathology confirmed that the engineered hucMSC-sEVs could reach the liver of mice and aggregate around activated hepatic stellate cells (aHSCs) with a significantly stronger anti-liver fibrosis effect of BMP7-loaded hucMSC-sEVs compared to those of blank or negative control-transfected hucMSC-sEVs. In vitro, BMP7-loaded hucMSC-sEVs promoted the phenotypic reversal of aHSCs and inhibited their proliferation to enhance the anti-fibrotic effects. Conclusion: These engineered BMP7-loaded hucMSC-sEVs offer a novel and promising strategy for the clinical treatment of liver fibrosis. Keywords: hucMSCs, sEVs, aHSCs, nanocarrier, BMP7 Graphical Liver fibrosis is a pathological change caused by excessive extracellular matrix (ECM) deposition in the liver due to various factors (eg, alcohol, drugs, viruses, and immunity), ultimately leading to abnormalities in the structure and function of the liver. 1 Currently, 1.5 billion people worldwide are affected by liver fibrosis, which is a typical pathological phase of several chronic liver diseases, representing a considerable threat to global health. 2 The main features of liver fibrosis include a large number of activated hepatic stellate cells (aHSCs) and the accumulation of excess ECM. 3 Quiescent hepatic stellate cells (qHSCs) are characterized by abundant lipid droplets (LDs) in their cytoplasm that can store triglycerides and vitamin A, which are crucial for liver regeneration, lipid metabolism, and immunological regulation. 4 However, when the liver sustains injury, HSCs undergo activation and migrate to the site of injury, where aHSCs acquire a myofibroblast-like phenotype, lose LDs, and express high levels of α-smooth muscle actin (α-SMA) and collagen type I (COLI). 5 The reversibility of liver fibrosis was reported to involve the conversion of the active HSCs phenotype into the quiescent phenotype. 6 Therefore, aHSCs are important targets for anti-fibrotic therapy. Mesenchymal stem cells (MSCs) are adult stem cells with immunomodulatory and tissue repair properties. 7 With the development of regenerative medicine, MSCs have been extensively exploited as superior seed cells in several fields of medical research. MSCs can alleviate liver fibrosis through various mechanisms. 8–10 However, a few studies have shown that there is a risk of immune rejection, microvascular occlusion, and tumorigenicity when exogenous MSCs enter the body.<su -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology